International Journal of Radiation Oncology*Biology*Physics
Clinical investigation
Brain
Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119)
Introduction
Melatonin, an indoleamine molecule (N-acetyl, 5-methoxytryptamine), plays an important role in a number of processes, including circadian-rhythm regulation, sleep disorders, seasonal reproduction, retinal physiology, immune function, intermediary metabolism (1, 2), and carcinogenesis (3). It is also a highly efficient and potent free-radical scavenger and antioxidant molecule. Physiologic blood levels of melatonin correlate with the total antioxidant capacity of the serum (4). Oral ingestion of microgram amounts of melatonin results in near-physiologic nocturnal blood levels of melatonin (5, 6). The oral bioavailability of milligram doses of oral melatonin from nutritional supplements is about 15% (7), and results in supraphysiologic melatonin levels.
Numerous studies demonstrated that physiologic and pharmacologic blood concentrations of melatonin inhibit tumorigenesis in a variety of in vivo and in vitro experimental models of neoplasia (6, 8, 9). A preliminary study demonstrated that pretreatment of rats bearing hepatomas for 2 weeks before a single dose of radiation was administered just before lights off, and then with a nontumor-inhibiting dose of melatonin also given just before lights off, had a marked radiosensitizing effect. Pretreatment of tumor-bearing rats with morning doses of melatonin were ineffective (10).
The great majority of human trials of melatonin for cancer treatment or supportive care have come from Lissoni et al. (11, 12) at the Ospedale San Gerardo (Monza, Italy). Two of their trials form the basis of the present trial. In the first trial, Lissoni et al. randomized 50 patients who had previously undergone radiation therapy for brain metastases from solid tumors and who subsequently had intracranial progression to either supportive care or supportive care and 20 mg/day of melatonin at 8:00 pm daily until further deterioration or death (11). Neurologic stability and survival were both higher in the melatonin arm. The second trial randomized 30 patients with glioblastoma multiforme to either radiation therapy alone (60 Gy) or radiation therapy and 20 mg/day of melatonin (12). The survival of patients receiving melatonin was significantly higher at 1 year, with 6 of 14 surviving in the melatonin arm, and only 1 of 16 in the control arm (p < 0.05).
The Radiation Therapy Oncology Group (RTOG) developed BR-0119 based on the two trials by Lissoni et al. (11, 12) and on experimental cancer work showing the circadian-stage dependence of melatonin’s antitumor action and its antitumor effects. The trial was designed to compare whole-brain radiation therapy alone to radiation therapy and 20 mg/day melatonin for patients with brain metastases from solid tumors. All previous trials administered melatonin in the evening. Preclinical data suggest that the timing of melatonin administration relative to radiation therapy may be important (3). Therefore, patients were randomly assigned to receive melatonin in the morning or in the evening. Because the previous trial of melatonin given during radiation therapy for patients with glioblastoma multiforme (12) showed a marked improvement in survival, it was decided to give melatonin concurrently with radiation therapy. Preclinical studies also support concurrent administration (3). All patients received radiation therapy in the afternoon, to eliminate time of treatment as a variable. Patients in the two arms were then compared with the RTOG historical database of patients treated for brain metastases, to determine if there was any evidence of increased survival in either arm. If such evidence is seen, a phase III trial will be run to confirm it.
Section snippets
Eligibility and randomization
Eligible patients were those with recursive partitioning analysis (RPA) Class 2 brain metastases (Zubrod performance status 0–1, and any of the following: ≥65 years of age, extracranial metastases, or uncontrolled primary tumor). The patients were not on concurrent chemotherapy. Patients were randomized to morning (am) or evening (pm) 20-mg melatonin, according to a permuted block design, balanced by institution. The randomization was stratified by planned chemotherapy (yes vs. no). Patients
Results
The trial opened May 21, 2002, and closed July 1, 2003. One hundred and thirty patients were accrued from 36 different institutions. One hundred and twenty-six were available for analysis (62 assigned to am melatonin, and 64 to pm melatonin). Four patients were excluded from analysis: one because the patient received systemic therapy for small-cell carcinoma after study entry, one was not a confirmed RPA Class II at time of registration, one refused treatment with melatonin, and one received no
Discussion
The majority of randomized trials showing the clinical efficacy of melatonin among cancer patients are from the group of Lissoni et al. (11, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32). Three independent randomized trials, including this trial, have been run (33, 34). It is noteworthy that all trials from the group of Lissoni et al. (11, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32) have had positive outcomes, but so far there have been no confirmatory publications
Conclusions
This trial did not confirm the hypothesis that 20 mg of melatonin improved survival in patients with solid tumors metastatic to the brain who were receiving palliative whole-brain radiotherapy. This is in contrast to a previous trial by Lissoni et al., in which 20 mg of melatonin produced a significant increase in 1-year survival among patients with brain metastases and neurologic progression after radiation therapy (11). The cause of this difference is not apparent. Further studies of the
References (37)
- et al.
Sample size considerations for studies comparing survival curves using historical controls
J Clin Epidemiol
(1988) - et al.
The Mini-Mental State Examination in general medical practice: Clinical utility and acceptance
Mayo Clin Proc
(1996) - et al.
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status
Eur J Cancer
(1999) - et al.
Importance of the Mini-Mental Status Examination in the treatment of patients with brain metastases: A report from the Radiation Therapy Oncology Group protocol 91–04
Int J Radiat Oncol Biol Phys
(2000) Pineal melatonin: Cell biology of its synthesis and of its physiological interactions
Endocr Rev
(1991)Melatonin: Multi-faceted messenger to the masses
Lab Med
(1994)- et al.
Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy
Curr Top Med Chem
(2002) - et al.
Melatonin: A hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin
J Pineal Res
(2003) - et al.
Variable bioavailability of oral melatonin
N Engl J Med
(1997) - et al.
Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance
Proc Natl Acad Sci USA
(1994)
The absolute bioavailability of oral melatonin (0091–2700)
J Clin Pharmacol
Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect
J Pharmacol Exp Ther
Effect of melatonin on experimental tumors under different photoperiods and times of administration
J Neural Transm
Melatonin radiosensitizes tumors and radioprotects normal tissues: Time-of-day dependency
Am Assoc Cancer Res
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms
Cancer
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone
Oncology
Chronobiology of the mammalian response to ionizing radiationPotential applications in oncology
Chronobiol Int
Chronomodulated chemotherapy and irradiation: An idea whose time has come?
Chronobiol Int
Cited by (53)
-
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline
2022, Practical Radiation Oncology -
Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives
2018, Critical Reviews in Oncology/HematologyCitation Excerpt :The pineal gland hormone melatonin (N-acetyl-5-methoxytryptamine) induces apoptosis of cancer cells in vitro and stimulates the immune system, including NK cells and Th1 lymphocytes (Srinivasan et al., 2008). Several small RCTs have tested the anticancer efficacy of oral melatonin, mostly at a daily dosage of 20 mg, alone or in combination with chemotherapy, radiotherapy or low-dose interleukin 2 in different types of advanced solid tumors (Berk et al., 2007; Brivio et al., 2010; Cerea et al., 2003; Lissoni, 2007; Lissoni et al., 1995; Lissoni et al., 1992; Lissoni et al., 1994a,1994b; Lissoni et al., 1999; Lissoni et al., 1994a, 1994b; Lissoni et al., 2008; Lissoni et al., 1996a; Lissoni et al., 2003; Lissoni et al., 1996b; Lissoni et al., 1997a; Lissoni et al., 1997b; Sookprasert et al., 2014; Yan et al., 2002). One meta-analysis of 8 RCTs found that melatonin improved both remission rates and 1 year survival rates compared with the placebo (Wang et al., 2012).
-
Role of drugs in the prevention and amelioration of radiation induced toxic effects
2018, European Journal of PharmacologyCitation Excerpt :Various in vitro and in vivo investigations have established radioprotection with melatonin and its analogues (El-Missiry et al., 2007; Manda et al., 2008, 2007; Tan et al., 1998). Clinical investigation of melatonin has been done in a phase II Radiation Therapy Oncology Group trial (Berk et al., 2007). This study reported that concurrent administration of melatonin with radiation was well tolerated but the treatment had no significant effect on survival time or neurologic function.
-
This study was supported by National Cancer Institute grants RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115.
Conflict of interest: none.